The Experts below are selected from a list of 192 Experts worldwide ranked by ideXlab platform

Zhang Xian-nan - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Nitroglycerin and nicorandil in the treatment of unstable angina
    Hainan Medical Journal, 2011
    Co-Authors: Zhang Xian-nan
    Abstract:

    Objective To observe and compare the clinical effect of Nitroglycerin and nicorandil in the treatment of unstable angina.Methods 80 patients with unstable angina treated from December 2009 to February 2011 were randomly assigned to Nitroglycerin group and nicorandil group,which were given Nitroglycerin or nicorandil therapy,respectively,and the clinical efficacies were observed.Results The electrocardiogram was improved greater in the nicorandil group than that in the Nitroglycerin group,especially 48 hours after the treatment,which had significant differences between the two groups(P0.05);the angina attack frequency and duration of pain of the two groups had no significant difference;the overall incidence of adverse reactions of the two groups had no significant difference.Conclusion For unstable angina,nicorandil is superior to Nitroglycerin in ECG and has lower incidence of hypotension than Nitroglycerin.

Karl Swedberg - One of the best experts on this subject based on the ideXlab platform.

  • Buccal versus intravenous Nitroglycerin in unstable angina pectoris.
    European journal of clinical pharmacology, 1991
    Co-Authors: Mikael Dellborg, G. Gustafsson, Karl Swedberg
    Abstract:

    The clinical syndrome of unstable angina includes patients with the first onset of angina, change in a previous stable pattern or the development of chest pain at rest. Administration of intravenous Nitroglycerin is established therapy in unstable angina. Buccal Nitroglycerin has been introduced as an alternative means of administering Nitroglycerin, which provides relief of anginal pain within 2 to 3 min and a sustained effect for 3 to 5 h. Twenty-nine patients admitted to the coronary care unit due to unstable angina were randomized to receive treatment with Nitroglycerin i.v. for 24 h or buccal Nitroglycerin every 4 h. Therapy was titrated according to haemodynamic effects. The mean dose of buccal Nitroglycerin was 4.42 mg versus 0.45 micrograms.kg-1.min-1 in the intravenous group. The efficacy of treatment was similar in the two groups. Buccal Nitroglycerin appeared to cause fewer adverse effects, especially less haemodynamic intolerance and headache, although the differences were not significant. Repeated administration of buccal Nitroglycerin appears to be a safe and well tolerated alternative to high-dose i.v. Nitroglycerin treatment in unstable angina pectoris.

Hu Ping - One of the best experts on this subject based on the ideXlab platform.

Steven Dinh - One of the best experts on this subject based on the ideXlab platform.

  • In vitro characterization of a solvent-controlled Nitroglycerin transdermal system
    Journal of Controlled Release, 1995
    Co-Authors: Ann Reese Comfort, Ihor Shevchuk, John H. Otte, Steven Dinh
    Abstract:

    A well-controlled solvent-based system for transdermal delivery of Nitroglycerin has been developed. This system is fully characterized with respect to the effect of ethanol and Nitroglycerin concentration in the reservoir on the steady-state flux profile in vitro. The Nitroglycerin flux and ethanol flux through the system and skin are linearly proportional to the ethanol concentration in the donor compartment of the system. The ethanol volume fraction in the donor controls the permeability of the CML/skin laminate. As ethanol concentration controls the flux of Nitroglycerin from the system through skin, it is possible to reduce intersubject variation in Nitroglycerin transdermal delivery through the transdermal system design.

Giuseppe Nappi - One of the best experts on this subject based on the ideXlab platform.

  • Comparative analysis of the neuronal activation and cardiovascular effects of Nitroglycerin, sodium nitroprusside and L-arginine.
    Brain Research, 2005
    Co-Authors: Cristina Tassorelli, Rosaria Greco, Donata Cappelletti, Giorgio Sandrini, Giuseppe Nappi
    Abstract:

    Abstract In this study, we compare the biological effects, Fos expression and cardiovascular responses induced in the rat, of different nitric oxide modulators (Nitroglycerin, sodium nitroprusside and l -arginine). Nitroglycerin and sodium nitroprusside induced a similar pattern of neuronal activation in several areas, which include the paraventricular and supraoptic nuclei of the hypothalamus, central nucleus of the amygdala, parabrachial nucleus, locus coeruleus, ventrolateral medulla and nucleus tractus solitarius. However, only Nitroglycerin activated the periaqueductal grey and nucleus trigeminalis caudalis. l -Arginine-induced neuronal activation was restricted to the paraventricular and supraoptic nuclei of the hypothalamus. As regards cardiovascular effect, both Nitroglycerin and sodium nitroprusside induced moderate hypotension (Nitroglycerin: −23.3%, sodium nitroprusside: −24.3%) that lasted 40 min in the case of sodium nitroprusside and 80 min in the case of Nitroglycerin. l -Arginine did not significantly influence blood pressure. These data suggest that Nitroglycerin, sodium nitroprusside and l -arginine are associated with different biological effects on both the central nervous system and the cardiovascular system. Of the NO-related drugs tested in this study, only Nitroglycerin confirmed its ability to activate brainstem areas implicated in nociception.